All News

SCAN Group takes ownership of an integrated care delivery organization, to expand its impact on the lives of vulnerable seniors.

The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.

Ali Khawar, former Department of Labor official, explains the original intent of a federal rule to reinforce the Mental Health Parity and Addiction Equity Act could be under threat as the Trump administration walks back enforcement.

While artificial intelligence (AI) is transforming community oncology, Nini Wu, MD, of Navista, emphasizes that success depends on patient access and infrastructure.

The ALPHA3 trial is exploring cemacabtagene ansegedleucel's (cema-cel) potential to enhance outcomes in patients who have relapsed/refractory large B-cell lymphoma, particularly those positive for minimal residual disease.

Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and guiding precision care.

Following President Donald Trump's most favored nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

HHS announces it is taking steps to implement President Trump’s Executive Order on prescription drug pricing. Keep up with the latest moves made in health policy under President Donald Trump's second administration. This timeline will be updated as orders and policy progress.

Sleep disorders and mental health complications were more common in adolescents or young adults who had HIV across the globe.

In an era that FDA Commissioner Marty Makary, MD, MPH, calls an "epidemic of distrust" toward health institutions, previously contained disease rates are rapidly rising, and vaccination rates are proceeding in the opposite direction.

Proposed Medicaid cuts risk increasing health disparities, leaving millions uninsured and limiting access to essential care for vulnerable populations.

The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background antifibrotic therapy.

Research presented at the American Thoracic Society (ATS) 2025 International Conference used FDA-approved tools to see how sleep can impact other parts of recovery for patients in the intensive care unit (ICU).

Childhood cancer survivors face heightened risks of chronic kidney disease and hypertension, necessitating urgent updates to monitoring guidelines for their long-term health.

The FDA previously approved Jivi in 2018 to treat adults aged 12 years and older with hemophilia A.

Over 500,000 US patients hospitalized with nonsevere COVID-19 saw no clinically significant benefit and potential harm associated with routine early antibiotic treatment, supporting antibiotic stewardship to limit unnecessary use.

The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.

Solutions depend on listening to individuals with lived experience, rebuilding trust, and recognizing the humanity of every patient, experts say.

According to news reports, Biden's cancer is aggressive and has reached the bones.

The tool could make it easier for clinicians to rule out melanoma without the need for excision.

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

Employers discover innovative strategies for enhancing employee engagement and access to care at the Greater Philadelphia Business Coalition on Health (GPBCH) Annual Conference, fostering actionable dialogue and collaboration.

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The meta-analysis of 9 studies showed high sensitivity with slightly lower specificity with the less-invasive option for detecting lung complications in patients with the autoimmune disease.

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial saturation, access, and long-term care distinct from other parts of the world.

CK Wang, MD, chief medical officer of COTA, highlights how a lack of screening tools and declining ob-gyn pipeline can compound historical disparities seen in Black women's access to care.